FINWIRES · TerminalLIVE
FINWIRES

HKG:2005

29 stories mentioning HKG:2005Updated 5d ago

Every FINWIRES story that references HKG:2005, newest first.

What's the latest news on HKG:2005?

Asia

SSY Group Gets Various Drug Registration, Production Approvals in China

SSY Group (HKG:2005) has obtained approval from China's National Medical Products Administration for the production and registration of three drugs, according to a Thursday filing with the Hong Kong bourse.The drugs comprise Emedastine Difumarate Eye Drops for temporary relief from allergic conjunctivitis, Perindopril Arginine Tablets to treat hypertension and congestive heart failure, and Peramivir and Sodium Chloride Injection 100ml to treat influenza A and B.The approval came as the drugs are regarded as passing the regulator's consistency evaluation.The pharma firm also obtained approval for the Bumetanide Injection after it was regarded as passing the consistency evaluation. The product is mainly used for the treatment of hypertension and edematous diseases.

HKG:2005
Asia

SSY Group Gets Bulk Drug Approval for Hypertension Drug in China

SSY Group (HKG:2005) obtained registration approval for Azilsartan Medoxomil Potassium to become a bulk drug for the preparations on the market from China's National Medical Products Administration.The drug is used to treat primary hypertension in adults, according to a Thursday filing by the pharmaceutical firm with the Hong Kong bourse.

HKG:2005
Asia

SSY Group Receives China Approval for Three Drugs

Pharmaceutical firm SSY Group (HKG:2005) received drug production and registration approvals for three products in China, according to a Hong Kong bourse filing Monday.The approval from China's National Medical Products Administration covers oseltamivir phosphate capsules to treat influenza A and B; drotaverine hydrochloride tablets to treat smooth muscle spasms; and metoclopramide tablets for nausea.

HKG:2005
Asia

SSY Group Gets China Nod for Vitamin B12 Injection

SSY Group (HKG:2005) obtained approval for its Cyanocobalamin (Vitamin B12) Injection from China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The approval came as the drug passed the regulator's consistency evaluation of the quality and efficacy of generic drugs.The injection is primarily used for megaloblastic anemia caused by intrinsic factor deficiency such as neuritis, the pharma firm said.

HKG:2005
Asia

SSY Group's Protein Test Kits Get Device Registration Certificates from Hebei Regulator

SSY Group's (HKG:2005) full-range C-reactive and Serum Amyloid A/C-reactive protein test kits obtained medical device registration certificates from the Hebei Provincial Drug Administration of China, according to a Wednesday Hong Kong bourse filing.The kits are used for in vitro quantitative detection of C-reactive protein and serum amyloid A levels in human serum, plasma, or whole blood samples.

HKG:2005
Asia

SSY Group Receives China Approval for Three Drugs

Pharmaceutical firm SSY Group (HKG:2005) said it received drug production and registration approvals for three of its products in China, according to a Hong Kong bourse filing Wednesday.The approval from China's National Medical Products Administration covers a fat-soluble vitamin injection, metformin hydrochloride tablets for type 2 diabetes, and doxazosin mesylate extended release tablets for benign prostatic hyperplasia and hypertension.

HKG:2005
Asia

SSY Group's Attributable Profit, Turnover Rise in Q1

SSY Group (HKG:2005) reported unaudited profit attributable to shareholders of the company of HK$171.2 million for the quarter ended March 31, up from HK$168.5 million in the year-ago period, according to a Hong Kong bourse filing on Monday.The Hong Kong-listed pharmaceutical product maker's turnover in the first quarter reached HK$1.23 billion, compared with HK$1.14 billion a year ago.

HKG:2005
Asia

SSY Group Gets Chinese Regulatory Nod for Production, Registration of Two Products

SSY Group (HKG:2005) said it received Chinese regulatory approval to begin drug production and registration of its diltiazem hydrochloride in injection form, according to a Hong Kong bourse filing Monday.The drug is mainly used to treat a heart condition known as supraventricular tachycardia and the emergency treatment of abnormally high blood pressure during surgery.The firm's propranolol hydrochloride injection was also approved for production and registration by China's National Medical Products Administration.The product is mainly used to treat supraventricular tachyarrhythmias and ventricular arrhythmias.

HKG:2005
Asia

SSY Group Gets Bulk Drug Approval for Edema Drug in China

SSY Group's (HKG:2005) furosemide was approved for registration by China's National Medical Products Administration to become a bulk drug for preparation on the market, according to a Tuesday Hong Kong bourse filing.The product is mainly used to treat various diseases with edema, hypertension, hyperkalemia and hypercalcemia.

HKG:2005

Showing 21-29 of 29

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:2005 in your portfolio
WheelAI
WheelAI
Analyze HKG:2005 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:2005